Eli Lilly’s Basal Insulin Outperforms Lantus In Trial
Big pharma Eli Lilly (LLY) said Monday that its drug candidate reduced blood sugar in diabetics more than another leading treatment. The company’s stock rose a fraction on the stock market today. The phase-three clinical trial showed Lilly’s basal insulin peglispro (BIL) outperformed Sanofi’s (SNY) Lantus in patients with type 2 diabetes, though it did not yet release the exact numbers. Lilly also said patients on BIL showed less weight gain than